Oxurion NV (XBRU:OXUR) Change In Receivables : €2.68 Mil (TTM As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Oxurion NV Change In Receivables?

Oxurion NV's change in receivables for the quarter that ended in Dec. 2023 was €3.81 Mil. It means Oxurion NV's Accounts Receivable declined by €3.81 Mil from Jun. 2023 to Dec. 2023 .

Oxurion NV's change in receivables for the fiscal year that ended in Dec. 2023 was €2.68 Mil. It means Oxurion NV's Accounts Receivable declined by €2.68 Mil from Dec. 2022 to Dec. 2023 .

Oxurion NV's Accounts Receivable for the quarter that ended in Dec. 2023 was €0.12 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Oxurion NV's Days Sales Outstanding for the six months ended in Dec. 2023 was 252.86.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Oxurion NV's liquidation value for the six months ended in Dec. 2023 was €-17.98 Mil.

Oxurion NV Change In Receivables Historical Data

The historical data trend for Oxurion NV's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxurion NV Change In Receivables Chart

Oxurion NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

1.08

0.70

-2.04

0.22

2.68

Oxurion NV Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Receivables	Get a 7-Day Free Trial															-1.00	-0.21	0.42	-1.13	3.81

Oxurion NV Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €2.68 Mil.

Oxurion NV (XBRU:OXUR) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Oxurion NV's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.115	/	0.083	*	91
=	252.86

2. In Ben Graham's calculation of liquidation value, Oxurion NV's accounts receivable are only considered to be worth 75% of book value:

Oxurion NV's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	1.674	-	19.736	+	0.75 * 0.115	+	0.5 * 0
=	-17.98

Oxurion NV Change In Receivables Related Terms

Thank you for viewing the detailed overview of Oxurion NV's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Oxurion NV (XBRU:OXUR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxurion NV (XBRU:OXUR) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

TG4:Germany

Address

Gaston Geenslaan 1, Leuven, BEL, B-3001

Website

https://www.oxurion.com

Oxurion NV is a clinical stage biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME). The Group's research and development facilities are located in Belgium .The Company is engaged in the development of drugs to treat back-of-the-eye diseases, more specifically, ophthalmologic pharmaceuticals to treat vascular retinal disorders, specifically DME.

Oxurion NV (XBRU:OXUR) Headlines

No Headlines